Total Payments
$1,629
2022 Payments
$35.54
Companies
24
Transactions
90
Medicare Patients
2,659
Medicare Billing
$125,774
Payment Breakdown by Category
Food & Beverage$1,334 (81.9%)
Education$294.46 (18.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,334 | 82 | 81.9% |
| Education | $294.46 | 8 | 18.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Pharmaceuticals, Inc | $253.39 | 20 | $0 (2019) |
| Astellas Pharma US Inc | $203.55 | 4 | $0 (2019) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $175.33 | 9 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $136.11 | 6 | $0 (2021) |
| Amgen Inc. | $134.62 | 6 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $119.19 | 8 | $0 (2021) |
| Genentech USA, Inc. | $86.34 | 3 | $0 (2019) |
| Actelion Pharmaceuticals US, Inc. | $78.67 | 6 | $0 (2022) |
| La Jolla Pharmaceutical Company | $63.18 | 1 | $0 (2018) |
| Grifols USA, LLC | $46.68 | 4 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $35.54 | 2 | Amgen Inc. ($20.64) |
| 2021 | $242.00 | 10 | Boehringer Ingelheim Pharmaceuticals, Inc. ($87.85) |
| 2020 | $161.38 | 7 | AstraZeneca Pharmaceuticals LP ($75.00) |
| 2019 | $373.62 | 19 | Astellas Pharma US Inc ($74.78) |
| 2018 | $573.53 | 34 | Janssen Pharmaceuticals, Inc ($163.10) |
| 2017 | $242.73 | 18 | Novartis Pharmaceuticals Corporation ($75.39) |
All Payment Transactions
90 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/15/2022 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $20.64 | General |
| Category: Inflammation | ||||||
| 01/03/2022 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Food and Beverage | In-kind items and services | $14.90 | General |
| Category: Cardiology | ||||||
| 09/28/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $76.20 | General |
| Category: DIABETES | ||||||
| 08/13/2021 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $13.89 | General |
| Category: Cardiology | ||||||
| 08/09/2021 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $12.77 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/10/2021 | Chiesi USA, Inc. | KENGREAL (Drug), CLEVIPREX | Food and Beverage | Cash or cash equivalent | $13.42 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/10/2021 | AstraZeneca Pharmaceuticals LP | BRILINTA (Drug) | Food and Beverage | In-kind items and services | $11.85 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/10/2021 | Merck Sharp & Dohme Corporation | VERQUVO (Drug) | Food and Beverage | In-kind items and services | $13.57 | General |
| Category: CARDIOVASCULAR | ||||||
| 04/21/2021 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $60.11 | General |
| Category: Cardiology | ||||||
| 04/21/2021 | Amarin Pharma Inc. | Vascepa (Drug) | Food and Beverage | In-kind items and services | $14.38 | General |
| Category: Cardiovascular | ||||||
| 04/14/2021 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $14.16 | General |
| Category: CARDIOVASCULAR | ||||||
| 04/05/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $11.65 | General |
| Category: RESPIRATORY | ||||||
| 10/28/2020 | AstraZeneca Pharmaceuticals LP | BRILINTA (Drug) | Education | In-kind items and services | $75.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/16/2020 | Amgen Inc. | Corlanor (Drug), Repatha | Food and Beverage | In-kind items and services | $13.40 | General |
| Category: Cardiology | ||||||
| 03/10/2020 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $15.44 | General |
| Category: RESPIRATORY | ||||||
| 03/09/2020 | PFIZER INC. | ELIQUIS (Drug), VYNDAQEL | Food and Beverage | In-kind items and services | $15.11 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 02/19/2020 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Food and Beverage | In-kind items and services | $14.79 | General |
| Category: Cardiology | ||||||
| 02/17/2020 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $11.17 | General |
| Category: Pulmonology | ||||||
| 01/17/2020 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $16.47 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 12/13/2019 | Amarin Pharma Inc. | Vascepa (Drug) | Food and Beverage | In-kind items and services | $10.96 | General |
| Category: Hypertriglyceridemia | ||||||
| 11/11/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $13.74 | General |
| Category: RESPIRATORY | ||||||
| 11/11/2019 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Education | In-kind items and services | $12.70 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/08/2019 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Education | In-kind items and services | $12.70 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/08/2019 | Preventice Services, LLC | — | Food and Beverage | Cash or cash equivalent | $16.87 | General |
| Category: Cardiovascular Monitors | ||||||
| 09/16/2019 | Philips Electronics North America Corporation | inCourage (Device) | Food and Beverage | Cash or cash equivalent | $14.32 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 11 | 1,002 | 1,215 | $124,152 | $46,856 |
| 2020 | 15 | 1,657 | 2,100 | $233,312 | $78,918 |
Total Patients
2,659
Total Services
3,315
Medicare Billing
$125,774
Procedure Codes
27
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 237 | 352 | $56,320 | $23,933 | 42.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 35 | 36 | $12,240 | $5,368 | 43.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 42 | 71 | $9,585 | $3,844 | 40.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 75 | 78 | $9,360 | $3,073 | 32.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 29 | 29 | $7,540 | $3,006 | 39.9% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 46 | 76 | $6,840 | $2,207 | 32.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 14 | 20 | $4,000 | $1,579 | 39.5% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2021 | 160 | 189 | $4,536 | $1,076 | 23.7% |
| 94726 | Determination of lung volumes using plethysmography | Facility | 2021 | 121 | 121 | $3,630 | $1,066 | 29.4% |
| 94060 | Measurement and graphic recording of the amount and speed of breathed air, before and following medication administration | Facility | 2021 | 122 | 122 | $7,076 | $919.98 | 13.0% |
| 94729 | Measurement of lung diffusing capacity | Facility | 2021 | 121 | 121 | $3,025 | $785.77 | 26.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 314 | 489 | $78,240 | $26,197 | 33.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 75 | 75 | $25,500 | $11,302 | 44.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 94 | 156 | $21,060 | $8,846 | 42.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 53 | 78 | $15,600 | $6,089 | 39.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 58 | 58 | $15,080 | $6,079 | 40.3% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 109 | 183 | $16,470 | $5,437 | 33.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 105 | 110 | $13,200 | $4,092 | 31.0% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2020 | 368 | 469 | $11,256 | $2,672 | 23.7% |
| 94060 | Measurement and graphic recording of the amount and speed of breathed air, before and following medication administration | Facility | 2020 | 134 | 134 | $7,772 | $1,316 | 16.9% |
| 94726 | Determination of lung volumes using plethysmography | Facility | 2020 | 135 | 135 | $4,050 | $1,261 | 31.1% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2020 | 14 | 14 | $2,800 | $1,107 | 39.5% |
| 31623 | Examination of lung airways using an endoscope | Facility | 2020 | 15 | 15 | $11,235 | $950.95 | 8.5% |
| 94729 | Measurement of lung diffusing capacity | Facility | 2020 | 135 | 135 | $3,375 | $933.21 | 27.7% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 23 | 23 | $3,220 | $921.84 | 28.6% |
About Dr. Philip Watson, DO
Dr. Philip Watson, DO is a Cardiovascular Disease healthcare provider based in Vincennes, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2005. The National Provider Identifier (NPI) number assigned to this provider is 1558368308.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Philip Watson, DO has received a total of $1,629 in payments from pharmaceutical and medical device companies, with $35.54 received in 2022. These payments were reported across 90 transactions from 24 companies. The most common payment nature is "Food and Beverage" ($1,334).
As a Medicare-enrolled provider, Watson has provided services to 2,659 Medicare beneficiaries, totaling 3,315 services with total Medicare billing of $125,774. Data is available for 2 years (2020–2021), covering 27 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Pulmonary Disease
- Location Vincennes, IN
- Active Since 07/07/2005
- Last Updated 04/03/2019
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1558368308
Products in Payments
- XARELTO (Drug) $253.39
- BRILINTA (Drug) $122.67
- ENTRESTO (Drug) $119.19
- LEXISCAN (Drug) $104.55
- Esbriet (Biological) $86.34
- JARDIANCE (Drug) $76.20
- Repatha (Biological) $74.00
- OFEV (Drug) $65.36
- GIAPREZA (Drug) $63.18
- UPTRAVI (Drug) $40.92
- Corlanor (Drug) $39.98
- LifeVest (Device) $38.97
- Pulmonx Endobronchial Valve EBV (Device) $32.08
- inCourage (Device) $25.94
- KENGREAL (Drug) $25.66
- ZERBAXA (Drug) $25.40
- Vascepa (Drug) $25.34
- Prolastin-C (Biological) $24.32
- OPSUMIT MACITENTAN (Drug) $22.96
- PRADAXA (Drug) $22.67
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.